<p>阿斯利康（AstraZeneca PLC）（NASDAQ:AZN - 获取免费报告）在周二交易前出现了跳空下跌。该股此前收于 71.43 美元，但开盘价为 67.14 美元。阿斯利康的最新交易价格为 66.72 美元，成交量为 2,053,509 股。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>现在可以购买的 5 只超卖股票</li>
</ul>
<p>最近，一些分析师对该公司发表了评论。TD Cowen 将阿斯利康的目标价从 90.00 美元上调至 95.00 美元，并在 8 月 12 日的报告中给予该公司 “买入” 评级。德意志银行将阿斯利康的股票评级从 “持有” 下调至 “卖出”，该报告于 9 月 13 日发布。最后，Erste Group Bank 在 9 月 11 日的研究报告中将阿斯利康的评级从 “持有” 上调至 “买入”。一位分析师给予该股票 “卖出” 评级，一位给予 “持有” 评级，七位给予 “买入” 评级，另外两位给予 “强烈买入” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 89.75 美元。</p>
<p><strong>阅读我们最新的阿斯利康股票分析</strong></p>
<h2>阿斯利康股价下跌 6.7%</h2>
<ul>
<li>抵御市场：3 只市值巨头股票飙升至新高</li>
</ul>
<p>该公司的市值为 2065.9 亿美元，市盈率为 32.11，市盈增长比率为 1.32，贝塔值为 0.47。该公司的 50 日移动平均线为 78.87 美元，200 日移动平均线为 78.77 美元。公司的债务与股本比率为 0.69，速动比率为 0.69，流动比率为 0.89。</p>
<h2>对阿斯利康的对冲基金看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Martin Investment Management LLC 在第三季度将其在阿斯利康的持股增加了 2.8%。Martin Investment Management LLC 目前拥有 284,204 股该公司的股票，价值 22,571,000 美元，此前在上个季度又购买了 7,615 股。Integrated Advisors Network LLC 在第三季度将其在阿斯利康的持股增加了 46.6%。Integrated Advisors Network LLC 目前拥有 43,610 股该公司的股票，价值 3,398,000 美元，此前在上个季度又购买了 13,860 股。Creative Planning 在第三季度将其在阿斯利康的持股增加了 8.0%。Creative Planning 目前拥有 224,751 股该公司的股票，价值 17,510,000 美元，此前在该期间又购买了 16,692 股。TD Asset Management Inc 在第一季度将其在阿斯利康的持股增加了 8.6%。TD Asset Management Inc 目前拥有 1,537,410 股该公司的股票，价值 104,160,000 美元，此前在上个季度又购买了 121,876 股。最后，Northcape Wealth Management LLC 在第二季度购买了阿斯利康的新头寸，价值约 269,000 美元。20.35% 的股票由机构投资者持有。</p>
<h2>阿斯利康公司简介</h2>
<p>（获取免费报告）</p>
<ul>
<li>阿斯利康股价下跌，尽管每股收益超出预期并上调了指引</li>
</ul>
<p>阿斯利康 PLC 是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵盖心血管、肾脏、代谢和肿瘤领域。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过阿斯利康</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>Palantir 突破 50 美元，是否还有机会入场？</li>
<li>如何计算通货膨胀率</li>
<li>内部人士购买信号显示这 3 只股票有上涨潜力</li>
<li>复利及其在投资中的重要性</li>
<li>这两大巨头将与埃隆·马斯克的 Starlink 竞争</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<p>→ 最后的边界（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIyNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIyNQ"/></p>
<h2>你现在应该投资 1000 美元在阿斯利康吗？</h2>
<p>在考虑阿斯利康之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿斯利康并不在名单上。</p>
<p>尽管阿斯利康目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿斯利康

<p>阿斯利康（NASDAQ:AZN）股票在交易前出现跳空下跌，开盘价为 0.14，前一交易日收盘价为 0.43。该股最后交易价格为 0.72，成交量超过 200 万股。分析师的评级意见不一：TD Cowen 上调至 “买入”，德意志银行下调至 “卖出”，Erste Group Bank 上调至 “买入”。市场共识评级为 “适度买入”，目标价为 0.75。机构投资者持有该股票的 20.35%。阿斯利康专注于生物制药，市值为 59 亿美元，市盈率为 32.11</p>

<p>Shares of AstraZeneca PLC (NASDAQ:AZN - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $71.43, but opened at $67.14. AstraZeneca shares last traded at $66.72, with a volume of 2,053,509 shares changing hands.</p>
<div class="lb-trans"><p>阿斯利康（AstraZeneca PLC）（NASDAQ:AZN - 获取免费报告）在周二交易前出现了跳空下跌。该股此前收于 71.43 美元，但开盘价为 67.14 美元。阿斯利康的最新交易价格为 66.72 美元，成交量为 2,053,509 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>5 Oversold Stocks to Buy Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在可以购买的 5 只超卖股票</li>
</ul>
</div><p>A number of analysts have recently commented on the company. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the company a &#34;buy&#34; rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Friday, September 13th. Finally, Erste Group Bank raised AstraZeneca from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $89.75.</p>
<div class="lb-trans"><p>最近，一些分析师对该公司发表了评论。TD Cowen 将阿斯利康的目标价从 90.00 美元上调至 95.00 美元，并在 8 月 12 日的报告中给予该公司 “买入” 评级。德意志银行将阿斯利康的股票评级从 “持有” 下调至 “卖出”，该报告于 9 月 13 日发布。最后，Erste Group Bank 在 9 月 11 日的研究报告中将阿斯利康的评级从 “持有” 上调至 “买入”。一位分析师给予该股票 “卖出” 评级，一位给予 “持有” 评级，七位给予 “买入” 评级，另外两位给予 “强烈买入” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 89.75 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AZN</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的阿斯利康股票分析</strong></p>
</div><h2>AstraZeneca Trading Down 6.7 %</h2>
<div class="lb-trans"><h2>阿斯利康股价下跌 6.7%</h2>
</div><ul>
<li>Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>抵御市场：3 只市值巨头股票飙升至新高</li>
</ul>
</div><p>The firm has a market cap of $206.59 billion, a P/E ratio of 32.11, a P/E/G ratio of 1.32 and a beta of 0.47. The firm has a fifty day moving average of $78.87 and a 200-day moving average of $78.77. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.</p>
<div class="lb-trans"><p>该公司的市值为 2065.9 亿美元，市盈率为 32.11，市盈增长比率为 1.32，贝塔值为 0.47。该公司的 50 日移动平均线为 78.87 美元，200 日移动平均线为 78.77 美元。公司的债务与股本比率为 0.69，速动比率为 0.69，流动比率为 0.89。</p>
</div><h2>Hedge Funds Weigh In On AstraZeneca</h2>
<div class="lb-trans"><h2>对阿斯利康的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Martin Investment Management LLC grew its position in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company's stock valued at $22,571,000 after buying an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company's stock worth $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Creative Planning lifted its position in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company's stock worth $17,510,000 after purchasing an additional 16,692 shares during the period. TD Asset Management Inc raised its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company's stock worth $104,160,000 after buying an additional 121,876 shares in the last quarter. Finally, Northcape Wealth Management LLC bought a new position in AstraZeneca during the second quarter valued at about $269,000. 20.35% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Martin Investment Management LLC 在第三季度将其在阿斯利康的持股增加了 2.8%。Martin Investment Management LLC 目前拥有 284,204 股该公司的股票，价值 22,571,000 美元，此前在上个季度又购买了 7,615 股。Integrated Advisors Network LLC 在第三季度将其在阿斯利康的持股增加了 46.6%。Integrated Advisors Network LLC 目前拥有 43,610 股该公司的股票，价值 3,398,000 美元，此前在上个季度又购买了 13,860 股。Creative Planning 在第三季度将其在阿斯利康的持股增加了 8.0%。Creative Planning 目前拥有 224,751 股该公司的股票，价值 17,510,000 美元，此前在该期间又购买了 16,692 股。TD Asset Management Inc 在第一季度将其在阿斯利康的持股增加了 8.6%。TD Asset Management Inc 目前拥有 1,537,410 股该公司的股票，价值 104,160,000 美元，此前在上个季度又购买了 121,876 股。最后，Northcape Wealth Management LLC 在第二季度购买了阿斯利康的新头寸，价值约 269,000 美元。20.35% 的股票由机构投资者持有。</p>
</div><h2>AstraZeneca Company Profile</h2>
<div class="lb-trans"><h2>阿斯利康公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance</li>
</ul>
<div class="lb-trans"><ul>
<li>阿斯利康股价下跌，尽管每股收益超出预期并上调了指引</li>
</ul>
</div><p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p>
<div class="lb-trans"><p>阿斯利康 PLC 是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵盖心血管、肾脏、代谢和肿瘤领域。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than AstraZeneca</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Palantir Cracks $50, Is There Still Time to Get on Board?</li>
<li>How to Calculate Inflation Rate</li>
<li>Insider Buying Signals Upside for These 3 Stocks</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>These 2 Big Players Are Set to Compete With Elon Musk’s Starlink</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过阿斯利康</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>Palantir 突破 50 美元，是否还有机会入场？</li>
<li>如何计算通货膨胀率</li>
<li>内部人士购买信号显示这 3 只股票有上涨潜力</li>
<li>复利及其在投资中的重要性</li>
<li>这两大巨头将与埃隆·马斯克的 Starlink 竞争</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><p>→ The Final Frontier (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 最后的边界（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIyNQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10225&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AstraZeneca right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在阿斯利康吗？</h2>
</div><p>Before you consider AstraZeneca, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿斯利康之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿斯利康并不在名单上。</p>
</div><p>While AstraZeneca currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管阿斯利康目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿斯利康（NASDAQ:AZN）股价跳空下跌 - 以下是原因